Brief: Valbiotis Announces First Patient's Visit In Phase II HEART Clinical Study

Valbiotis SA

22/02/2021 16:50

Feb 22 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES THE FIRST PATIENT’S FIRST VISIT IN THE
PHASE
II HEART CLINICAL STUDY ON TOTUM-070 AND STEPS UP ITS RESEARCH
PROGRAM AGAINST HYPERCHOLESTEROLEMIA IN 2021
    * DEVELOPMENT PROGRAM WILL PROVIDE COMPREHENSIVE DATA IN
EARLY
2022 TO POSITION TOTUM-070 AS A BREAKTHROUGH INNOVATION IN
CARDIOVASCULAR RISK PREVENTION MARKET.
    * EXTENSIVE PRECLINICAL WORK WILL SIMULTANEOUSLY BE
CONDUCTED ON
RESEARCH AND DEVELOPMENT PLATFORM AND SUBMITTED TO AMERICAN
HEART ASSOCIATION (AHA) ANNUAL MEETING IN NOVEMBER 2021
    * HEART STUDY WILL INCLUDE 120 PEOPLE WITH ELEVATED BLOOD
LDL-CHOLESTEROL
    * WILL CARRY OUT A CLINICAL STUDY ON TOTUM-070 IN 2021 TO
CHARACTERIZE ALL METABOLITES OF THIS ACTIVE SUBSTANCE AND
IDENTIFY THEIR EFFECTS ON HUMAN CELL MODELS
    * HEART: RESULTS ARE EXPECTED IN EARLY 2022

Source text for Eikon:  ID:nBw8f3C4Sa 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))